PAN1

A randomised phase II study evaluating potential predictive biomarkers in the treatment of locally advanced and metastatic pancreatic cancer.

Share

Trial Status

Completed

Cancer Type

Pancreatic Cancer

Aim

To prospectively evaluate hENT1 as a predictive marker of benefit from gemcitabine treatment in locally advanced and metastatic pancreatic cancer.

Summary

The PAN1 study Trial Management Committee recommended closure of the study to further randomization, effective from Friday the 22nd of February 2013, following a decision by the funders to cease support for the study.

Trial Status

Completed

Cancer Type

Pancreatic Cancer

Conference Presentation Reference

  1. Chua YJ, Karapetis CS, Gebski V, O’Connell R, Begbie S, Nott LM, Cronk MF, Underhill C, Abdi EA, Van Hagen T, Wong N, Hall M, Ferraro DA, Sjoquist KM, Santos C, Mackey JR, Goldstein D. Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) treated patients with metastatic pancreatic cancer: the randomized phase II PAN1 study. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.
  2. Chua Y, Karapetis C, Underhill C, Nott L, Goldstein D, Cronk M, Gebski V, Wong N, Sjoquist K, Biankin A. PAN1: a randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract TPS4137

Aim

To prospectively evaluate hENT1 as a predictive marker of benefit from gemcitabine treatment in locally advanced and metastatic pancreatic cancer.

Summary

The PAN1 study Trial Management Committee recommended closure of the study to further randomization, effective from Friday the 22nd of February 2013, following a decision by the funders to cease support for the study.

Principal Investigator

Dr Yu Jo Chua

Funding

Avner Nahmani Foundation